Related references
Note: Only part of the references are listed.
Article
Rheumatology
Charalampos Papagoras et al.
Summary: Vaccinated patients with systemic rheumatic diseases who experience breakthrough COVID-19 have better outcomes compared to unvaccinated patients with similar disease characteristics. This highlights the importance of COVID-19 vaccination in vulnerable populations like those with SRDs.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Medicine, General & Internal
Srinivasa Vittal Katikireddi et al.
Summary: The study found that the vaccine protection of ChAdOx1 nCoV-19 against severe COVID-19 outcomes decreased within three months of the second dose in both Scotland and Brazil. Booster vaccine doses may be needed for individuals who have received ChAdOx1 nCoV-19.
Article
Biochemistry & Molecular Biology
Henning Gruell et al.
Summary: This study demonstrates that neutralization of the SARS-CoV-2 Omicron variant is greatly reduced in individuals who received two doses of the COVID-19 vaccine or have recovered from the disease, but is significantly increased after a booster vaccine dose.
Article
Biochemistry & Molecular Biology
Samuel M. S. Cheng et al.
Summary: Specific antibody levels against the SARS-CoV-2 Omicron variant decrease significantly after two doses of BNT162b2 or CoronaVac vaccines, but can be markedly increased with a booster dose of BNT162b2. Individuals who previously received two doses of BNT162b2 or CoronaVac showed reduced serum antibody titers against Omicron, while a BNT162b2 booster dose increased the antibody levels in the majority of individuals. This suggests mRNA vaccine boosters may be necessary in countries primarily using CoronaVac vaccines to combat the spread of Omicron.
Article
Oncology
A. L. Schmidt et al.
Summary: This study analyzes the clinical features of cancer patients who develop symptomatic COVID-19 after vaccination. It finds that these patients often have comorbidities and can experience severe and even lethal infections. Hematologic malignancy patients are over-represented among the vaccinated cancer patients who develop symptomatic COVID-19. Therefore, while vaccination remains crucial in protecting vulnerable populations, including cancer patients, those who develop breakthrough infections despite full vaccination still face the risk of severe outcomes.
ANNALS OF ONCOLOGY
(2022)
Article
Immunology
Sukhyun Ryu et al.
Summary: We estimated the mean serial interval and superspreading potential of the Delta variant in South Korea. The intervals were similar during two different study periods, as were the proportions of cases responsible for the majority of transmissions.
EMERGING INFECTIOUS DISEASES
(2022)
Article
Immunology
Marc Lipsitch et al.
Summary: The study evaluates the impact of breakthrough SARS-CoV-2 infections in vaccinated individuals and discusses the challenges in measuring breakthrough infections and determining the factors affecting vaccine effectiveness. The research also addresses key questions on transitioning to endemicity, tracking viral variants, identifying immune correlates of protection, and dealing with public health challenges in countering breakthrough infections amid global vaccine shortages.
NATURE REVIEWS IMMUNOLOGY
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Xiaoyu Han et al.
Summary: The study found that over one-third of severe COVID-19 patients showed fibrotic-like changes in the lung at 6-month follow-up CT, which were associated with older age, acute respiratory distress syndrome, longer hospital stays, tachycardia, noninvasive mechanical ventilation, and higher initial chest CT score.
Article
Respiratory System
Aditi S. Shah et al.
Summary: The long-term respiratory morbidity of COVID-19 remains unclear. A study found that a significant percentage of previously hospitalized patients had persisting abnormalities in clinical, radiological, and pulmonary function, highlighting the importance of developing treatment strategies and long-term respiratory follow-up.
Article
Medicine, General & Internal
Mark W. Tenforde et al.
Summary: This study evaluated the association between mRNA COVID-19 vaccines and COVID-19 hospitalization, as well as disease progression to critical illness among hospitalized patients. The results showed that vaccination with mRNA COVID-19 vaccines significantly decreased the likelihood of COVID-19 hospitalization and disease progression to death or mechanical ventilation.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Article
Medicine, General & Internal
Sara Y. Tartof et al.
Summary: This study aimed to assess the overall and variant-specific effectiveness of the BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19-related hospital admissions among members of a healthcare system in California. The effectiveness of the vaccine remained high against hospital admissions even up to 6 months after full vaccination, despite a decline in effectiveness against SARS-CoV-2 infections over time, which was likely due to waning immunity rather than the delta variant escaping vaccine protection.
Article
Medicine, General & Internal
Ann R. Falsey et al.
Summary: The clinical trial in the United States, Chile, and Peru showed that the AZD1222 vaccine was both safe and effective in preventing symptomatic and severe Covid-19 cases, with an overall estimated efficacy of 74% and a higher efficacy of 83.5% in participants 65 years of age or older. The high vaccine efficacy was consistent across various demographic subgroups, and antibodies increased significantly after each dose.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Hiam Chemaitelly et al.
Summary: In a study conducted in Qatar involving over 900,000 participants, vaccine effectiveness peaked at 77.5% in the first month after the second dose. However, it declined afterwards to as low as 20% in months 5 through 7 after vaccination, while protection against severe Covid-19 remained above 90% for at least 6 months.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Review
Respiratory System
Ruben J. Mylvaganam et al.
Summary: Post-acute sequelae of COVID-19, such as pulmonary fibrosis, may affect 10-30% of survivors and be associated with major morbidity. Mechanistic understanding of PASC-pulmonary fibrosis is crucial for determining therapeutic options and requires well-designed cohort studies and prospective clinical registries.
EUROPEAN RESPIRATORY REVIEW
(2021)
Article
Medicine, General & Internal
Eric J. Haas et al.
Summary: This study assessed the real-world effectiveness of the Pfizer-BioNTech mRNA COVID-19 vaccine BNT162b2 in Israel, showing high efficacy in preventing SARS-CoV-2 infections, hospitalizations, severe disease, and death. As vaccine coverage increased, there were marked declines in SARS-CoV-2 outcomes, indicating that COVID-19 vaccination can help control the pandemic.
Letter
Medicine, General & Internal
Nicole Doria-Rose et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Jamie Lopez Bernal et al.
Summary: This study estimated the real-world effectiveness of Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S vaccines against confirmed COVID-19 symptoms, hospital admissions, and deaths. The vaccines showed significant reduction in symptomatic COVID-19 among older adults and further protection against severe disease. Both vaccines demonstrated similar effects and protection was maintained for over 6 weeks.
BMJ-BRITISH MEDICAL JOURNAL
(2021)
Article
Pediatrics
Jose Villar et al.
Summary: This study evaluated the risks associated with COVID-19 in pregnancy on maternal and neonatal outcomes compared with pregnant individuals without COVID-19, finding that pregnant individuals with COVID-19 were at higher risk for various complications such as preeclampsia, severe infections, and preterm birth. The findings emphasize the importance for pregnant individuals and clinicians to strictly implement recommended COVID-19 preventive measures.
Article
Medicine, General & Internal
Adeel A. Butt et al.
Summary: The study evaluated the short-term effectiveness of SARS-CoV-2 vaccines in preventing infection in a real-world setting. The results showed that the currently used vaccines are highly effective in preventing confirmed infection in a high-risk population, whether it is the Pfizer-BioNTech BNT-162b2 vaccine or the Moderna mRNA-1273 vaccine.
ANNALS OF INTERNAL MEDICINE
(2021)
Article
Infectious Diseases
Tal Brosh-Nissimov et al.
Summary: A study in Israel showed that a minority of fully vaccinated individuals with significant comorbidities may still develop severe COVID-19, with a high mortality rate. Further research on this vulnerable population may help improve their protection.
CLINICAL MICROBIOLOGY AND INFECTION
(2021)
Article
Medicine, General & Internal
Moriah Bergwerk et al.
Summary: Among fully vaccinated health care workers, breakthrough infections with SARS-CoV-2 were correlated with neutralizing antibody titers during the peri-infection period. Most breakthrough infections were mild or asymptomatic, although persistent symptoms did occur.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Environmental Sciences
Dimitra S. Mouliou et al.
Summary: The study analyzed the potential severity of the COVID-19 pandemic in Volos, Greece, and found that four-fifths of participants reported comorbidities that could increase vulnerability to severe COVID-19. Respiratory symptoms were mainly reported by the unemployed and retirees, while cold-related symptoms were mainly reported in the education sector and among undergraduates.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
(2021)
Article
Health Care Sciences & Services
Paul Naaber et al.
Summary: The study found that antibody levels declined at 12 weeks and 6 months after receiving two doses of BNT162b2 vaccine, with Spike antibody levels at 6 months being similar to those in individuals who received one dose or had recovered from COVID-19. Most individuals developed Spike-specific memory T cell responses, which were lower in those with higher T cell immunosenescence. Antibody response was negatively correlated with age and positively correlated with the total score of vaccination side effects.
LANCET REGIONAL HEALTH-EUROPE
(2021)
Article
Respiratory System
Xiaohe Li et al.
Summary: Older age, higher BMI, severe/critical condition, fever, longer viral clearance time, pre-existing disease, and delayed hospitalization were identified as risk factors for developing persistent pulmonary fibrosis in COVID-19 patients. About one-third of fibrotic patients could reverse their condition after around 120 days from onset, and less than half of the patients had their lung function return to normal condition after three months from onset. An effective predictive model with an average AUC of 0.84 was established for early diagnosis of the persistence of pulmonary fibrosis in COVID-19 patients.
RESPIRATORY RESEARCH
(2021)
Article
Health Care Sciences & Services
Gili Regev-Yochay et al.
Summary: The study found that the BNT162b2 vaccine is moderately to highly effective in reducing infectivity by preventing infection and reducing viral shedding.
LANCET REGIONAL HEALTH-EUROPE
(2021)
Article
Infectious Diseases
Sun Bean Kim et al.
Summary: Efforts to control the spread of COVID-19 have been ongoing, with numerous clinical studies aiming to find treatment options. Effective treatments have been discovered, but there is a need for evidence-based methodology to continuously check for and update recommendations based on new evidence.
INFECTION AND CHEMOTHERAPY
(2021)
Article
Medicine, General & Internal
Nanshan Chen et al.
Article
Medicine, General & Internal
Giacomo Grasselli et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2020)
Article
Medicine, General & Internal
Fei Zhou et al.
Article
Medicine, General & Internal
David A. Berlin et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2020)
Review
Immunology
Luis F. Garcia
FRONTIERS IN IMMUNOLOGY
(2020)
Letter
Medicine, General & Internal
Angelo Carfi et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2020)
Review
Cell Biology
Casey A. Pollard et al.
PHYSIOLOGICAL GENOMICS
(2020)
Article
Respiratory System
Yiying Huang et al.
RESPIRATORY RESEARCH
(2020)
Article
Medicine, General & Internal
Yu-miao Zhao et al.
